Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Mesothelioma, Malignant × lenvatinib × 1 year × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1 Other solid neoplasm 1

Conditions

Carcinoma, Hepatocellular 35 Parkinson Disease 4, Autosomal Dominant Lewy Body 26 Carcinoma, Renal Cell 21 Melanoma 10 Endometrial Neoplasms 10 Neoplasms 9 Cholangiocarcinoma 8 Biliary Tract Neoplasms 7 Uterine Cervical Neoplasms 6 Liver Neoplasms 6 Squamous Cell Carcinoma of Head and Neck 5 Triple Negative Breast Neoplasms 4 Thyroid Neoplasms 4 Stomach Neoplasms 4 Recurrence 4 Ovarian Neoplasms 4 Colorectal Neoplasms 4 Carcinoma, Non-Small-Cell Lung 4 Neuroendocrine Tumors 3 Neoplasm Metastasis 3 Esophageal Squamous Cell Carcinoma 3 Diabetes Mellitus, Insulin-Dependent, 12 3 Breast Neoplasms 3 Adenocarcinoma 3 Vulvar Neoplasms 2 Uveal Melanoma 2 Small Cell Lung Carcinoma 2 Sarcoma 2 Pancreatic Neoplasms 2 Kidney Neoplasms 2

Interventions

Cisplatin 15 Pemetrexed 12 pembrolizumab 8 Nivolumab 8 Carboplatin 7 Ipilimumab 5 Cyclophosphamide 5 Platinum 4 1,2-diaminocyclohexaneplatinum II citrate 4 Gemcitabine 3 Drug Therapy 3 tremelimumab 2 fludarabine 2 durvalumab 2 atezolizumab 2 Radiotherapy, Intensity-Modulated 2 Radiotherapy 2 Radiation 2 Photochemotherapy 2 Methotrexate 2 Interleukin-2 2 Chemotherapy, Adjuvant 2 sargramostim 1 olaparib 1 niraparib 1 nintedanib 1 methoxyamine 1 lenvatinib 1 enzalutamide 1 decitabine and cedazuridine drug combination 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06318286 2025-05-25

PENINSULA

Hyogo Medical University

Phase 2 Recruiting

Other solid neoplasmThoracic

Mesothelioma, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon ⚡